Trial Optimizer

Trial Optimizer, developed by PhaseV, is an AI/ML-powered platform designed to transform clinical trial design and implementation for sponsors and CROs. By simulating millions of adaptive, Bayesian, and fixed trial designs at speed, Trial Optimizer enables biotech and pharmaceutical companies to reduce sample sizes, cut costs, and improve the probability of trial success across Phase 1 through Phase 3 studies.

The platform is purpose-built for clinical teams seeking smarter, data-driven approaches to trial design — from early-phase dose-finding studies through seamless late-phase pivotal trials. Trial Optimizer bridges the gap between conventional fixed designs and sophisticated adaptive methodologies, making advanced statistical approaches accessible within a single end-to-end platform.

Core Capabilities

• Run millions of trial simulations within minutes using AI/ML-driven computation
• Reduce trial sample size while preserving Type I error and statistical power constraints, yielding significant cost savings
• Perform optimization and sample size re-estimation across a broad range of Phase 1–2 and Phase 2–3 designs, including BOIN12, Seamless 2/3, and Response-Adaptive Randomization, among others
• Leverage causal ML-driven insights from previous trials and real-world data (RWD) to inform the design of future studies
• Support adaptive, Bayesian, and fixed trial design frameworks within a single multi-modal platform

Optimizer Snapshot: Real-Time Decision Support

• Simulate the impact of millions of adaptive and Bayesian design features with a single click
• Enable real-time multi-stakeholder decision-making throughout the trial lifecycle
• Intervene early with confidence and adapt trial parameters during the course of a study
• Reduce trial costs and duration while simultaneously increasing the probability of success

Key Results and Demonstrated Outcomes

• PhaseV adaptive designs have achieved a 10–40% reduction in sample size
• Similar reductions in trial costs and duration have been observed without compromising statistical power
• Real-time evaluation of trial parameters maximizes the probability of study success
• Turning complex data analysis into actionable insights helps reduce failure rates and optimize trial investments

Key Benefits for Sponsors and CROs

• Real-time evaluation of various trial parameters and their impact on overall study outcomes
• Improved patient outcomes through more efficient and better-designed clinical studies
• End-to-end integration of causal ML insights from historical trial data and real-world data into prospective trial design
• A unified platform that replaces fragmented legacy tools with a single, superior integrated offering

Trial Optimizer is part of the broader PhaseV platform, headquartered in Cambridge, MA. The solution is designed for biotech and pharma organizations looking to modernize their clinical development programs through AI-driven design optimization, with the platform accessible via demo request for teams ready to explore its capabilities.